Patrizia Cavazzoni, key FDA official, to leave agency
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...
STAT14d
Patrizia Cavazzoni, head of FDA’s drug center, to leave the agency
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
FiercePharma15d
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire from the agency. The seven-year FDA veteran communicated the decision in ...
Las Vegas Sun12d
Alternative remedies prescribed as FDA weighs whether to pull plug on drug
Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...
Yahoo Finance15d
FDA CDER director Patrizia Cavazzoni announces resignation
The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald ...
GlobalData on MSN15d
FDA CDER director Patrizia Cavazzoni announces resignation
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
Investing12d
RBC Capital sees FDA shakeup as risk to biotech stocks
On Monday, the biotechnology sector faced new uncertainties as RBC Capital Markets analysts highlighted potential risks following the resignation of Dr. Patrizia Cavazzoni from the U.S. Food and ...
JD Supra5d
Drugs and Biologics at FDA: Reflections on 2024 Activity Shed Light on the Road Ahead
With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...
Investing12d
RBC Capital sees FDA shakeup as risk to biotech stocks
On Monday, the biotechnology sector faced new uncertainties as RBC Capital Markets analysts highlighted potential risks following the resignation of Dr. Patrizia Cavazzoni from the U.S. Food and Drug ...